Hospital Acquired Infection (HAI) Control Markets

  • ID: 4115662
  • Report
  • 242 Pages
  • Kalorama Information
1 of 6

FEATURED COMPANIES

  • 3M
  • Alere
  • Belimed
  • Danaher Corporation
  • Glaxosmithkline Plc
  • Roche
  • MORE

Hospital Acquired Infection (HAI) Control Markets

Hospital Acquired Infection (HAI) Control Markets provides a revenue analysis for the prevention, testing, and treatment of infections in the healthcare surroundings, including the world revenues for 2010-2021 for hospital infection control, for hospital infection treatment, and for hospital infection prevention equipment and consumables (sterilization/disinfection). Sales information is also provided for the different market segments by primary geographic region (United States, Europe, rest of world) and leading manufacturers’ shares. Merck, Pfizer, GlaxoSmithKline, and Bayer are among the key companies in HAI control markets are among those manufacturers featured in the report’s competitor analysis.

The report provides a market analysis for each of three areas: prevention (sterilization and disinfection equipment), testing, and treatment, detailing the following market data:

  • The Global Market for Hospital Infection Control, 2010-2021
  • The Global Market for Hospital Infection Prevention Equipment and Consumables (Sterilization/Disinfection), 2010-2021
  • Th Global Market for Hospital Infection Prevention (Sterilization/Disinfection) Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • Market Value for Infection Prevention Equipment and Related Consumables by Product Type, 2016 (Medical Device/Instrument Sterilization, Wide-Area/Room Sterilization, Medical-grade Disinfection Solutions, Other Products, Total)
  • Market Value for Infection Prevention Equipment and Related Consumables by Technology, 2016 (Heat/Steam, Gas/Chemical, Ultrasound, Other, Total)
  • The Global Market for Hospital Infection Prevention (Sterilization/Disinfection), Leading Suppliers’ Shares, Estimates for 2016
  • The Global Market for Hospital Infection Testing/Diagnostics, 2010-2021
  • The Global Market for Hospital Infection Testing/Diagnostics, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • The Global Market for Hospital Infection Testing/Diagnostics Leading Suppliers’ Shares Estimates for 2016
  • The Global Market for Hospital Infection Treatment, 2010-2021
  • The Global Market for Hospital Infection Treatment Estimated Products, Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • The Global Market for Hospital Infection Treatment, Leading Suppliers' Shares, Estimated Share for HAIs for 2016
  • Annual Sales of Select Antibacterial Products, 2016
  • The Global Market for Hospital Infection Control, Estimated Market Share by Segment, 2016 (Treatment, Prevention, Testing)
  • The Global Market for Hospital Infection Control Estimated Market Share by Facility Setting, 2016 (Hospitals, Outpatient Servicing Centers, Dialysis Centers, Nursing Homes, Community Clinics, Others)
  • The Global Market for Hospital Infection Control Estimated Market Share by Hospital Department, 2016 (ICU, Med/Surg, Pediatrics, Others)
  • The Global Market for Hospital Infection Control, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • The Global Market for Hospital Infection Control, Estimated Product Sales by Geographic Region, 2010-2021 (United States, Europe, Rest of World)
  • The Global Market for Hospital Infection Control, Estimated Market Share by Geographic Region, 2016 (%) (United States, Europe, Rest of World)
  • The Global Market for Hospital Infection Control, Estimated Market Share by Region, 2016 (%) (Developed Europe, Emerging Europe, United States, Rest of World [Japan, India, Canada, Brazil, China, Mexico, Africa, Other Developed, Other Emerging])
  • Global Markets for HAI by Participant and Segment (Infection Prevention, Infection Diagnostics, Infection Treatment)

A nosocomial infection is a new infection that develops in a patient during hospitalization or during a stay at a health facility. It is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, so infections incubating, but not clinically apparent, at admission are excluded. This type of infection is also known as a hospital-acquired infection (or, more generically, healthcare associated infection). The report provides the following data regarding nosocomial infections:

  • Frequency of the Most Common Nosocomial Infections
  • Market Value for Nosocomial Infection Diagnostics by Class, 2016 (Immunoassays, Microbial Identification / Antimicrobial Sensitivity (ID/AST), Molecular DNA, Total)
  • Market Value for Nosocomial Infection Diagnostics by Pathogen Target, 2016 (C. difficile Infections; MRSA Infections; Enterococcus, vancomycin-resistant; Enterobacteriaceae, carbapenem-resistant; M Tuberculosis; Others; Total)
  • Market Value for Nosocomial Infection Treatments by Class, 2016 (Quinolones, Glycopeptides, ß-lactamase inhibitors, Tetracyclines, Oxazolidinones, Macrolides, Carbapenems, Cephalosporins, Penicillins, Combinations, Others, Total)
  • Nosocomial Infection Drug Candidates by Class, 2016 (Quinolones, Glycopeptides, Aminoglycosides, Tetracyclines, Oxazolidinones, Macrolides, Pleuromutilins, Cephalosporins, Fabl inhibitors, Combinations, Others, Total)
  • Market Value for Nosocomial Infection Treatments by Pathogen Target, 2016 (ABSSSI, cUTI, MRSA Infections, HAP/VAP, C. Difficile Infections, Others, Total)

Hospital acquired infections share many of the challenges faced by the larger healthcare industry. Both challenges and industry trends are discussed in Hospital Acquired Infection (HAI) Control Markets, as well as market growth drivers and market growth inhibitors. One of the challenges facing the market is that increased attention to identification in the emergency department (ED) is needed to reduce risk and control exposure. With rapid identification, placing patients in isolation, whether they are colonized or infected, will likely make a difference in the resistance rates and spread of microorganisms in hospitalized patients. 

The majority of competitive participation for healthcare infection control is in the United States and Europe. However, competition is steadily escalating in these areas, which is encouraging more participation in other regions such as Asia and Latin America. The report profiles important players in the current competitive landscape, including:

  • 3M
  • Abbott Laboratories
  • AbbVie
  • Advanced Sterilization Products
  • Alere
  • AstraZeneca
  • Bayer
  • Becton, Dickinson
  • Belimed
  • bioMérieux
  • Cantel Medical
  • Danaher
  • Ecolab
  • Getinge AB
  • GlaxoSmithKline
  • Merck & Co.
  • Pfizer, Inc.
  • Roche (F. Hoffman-La Roche, Ltd.)
  • Sakura Seiki, Co., Ltd.
  • Steris plc
  • TSO3

Market analysis in this report considers primarily the epidemiological considerations and the size of patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis. Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital and primary care environment in order to construct a picture of the infection prevention, testing and treatment needs.

READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • 3M
  • Alere
  • Belimed
  • Danaher Corporation
  • Glaxosmithkline Plc
  • Roche
  • MORE

CHAPTER ONE: EXECUTIVE SUMMARY

OVERVIEW THE NOSOCOMIAL INFECTION

  • Table 1-1: Frequency of the Most Common Nosocomial Infections

MARKET SCOPE

RESEARCH METHODOLOGY

INDUSTRY CHALLENGES

  • Table 1-2: Growth Drivers and Inhibitors

TOTAL SIZE AND GROWTH OF THE MARKET

  • Table 1-3: The Global Market for Hospital Infection Control, 2010-2021
  • Figure 1-1: Global Market for Hospital Infection Control, 2010-2021

ISSUES AND TRENDS AFFECTING MARKET

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
OVERVIEW

  • Introduction to Pathogens
  • Classification of Antibacterial Organisms

COMMON HOSPITAL (NOSOCOMIAL) INFECTIONS
DESCRIPTION OF INFECTIONS

  • Acinetobacter Baumannii
  • Clostridium Difficile
  • Gastroenteritis
  • Hospital-Acquired Pneumonia (HAP)
  • Pseudomonas Aeruginosa
  • Staphylococcus Aureus/Methicillin-Resistant Staphylococcus Aureus
  • Stenotrophomonas Maltophilia
  • Tuberculosis
  • Urinary Tract Infections
  • Vancomycin-Resistant Enterococcus
  • Ventilator-Associated Pneumonia (VAP)
  • Patient Risk Factors
  • General Populations at Risk for Infection
  • Hospital Acquired Infection (HAI) Control Markets
  • Table 2-1: Global Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region (Cancer [newly diagnosed; active treatment], Diabetes, HIV/AIDS, Surgical Procedure, ESRD/Dialysis, Organ Transplants, Cystic Fibrosis; United States, Europe, Other Regions, World)

WORLD DEMOGRAPHICS

  • Figure 2-1: The Global Population, 2005-2050
  • Table 2-2: Global Population Trends Age 65+, 2000-2050
  • Assessing the Problem: Nosocomial Infection Statistics
  • Figure 2-2: U.S. Hospital Admissions and Percent of Hospital Acquired Infections (HAIs) (MRSA, C. diff, Others)
  • Figure 2-3: European Union Hospital Admissions and Percent of Hospital Acquired Infections (HAIs) (SSI, Bloodstream, MRSA, Lower RTI, UTI, Others)
  • Hospital Length of Stay
  • U.S. GOVERNMENT'S NATIONAL PLAN TO PREVENT HEALTHCARE ASSOCIATED INFECTIONS (HAIS)

STEERING COMMITTEE
EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASES
AFFORDABLE CARE ACT (ACA) FUNDING
EMERGING INFECTIONS PROGRAM

  • Table 2-3: U.S. States ACA HAI Prevention Infrastructure Funding Awards, 2013-2016

THE DEPARTMENT OF HEALTH AND HUMAN SERVICES: 2017 BUDGET HIGHLIGHTS

  • Table 2-4: U.S. Department of Health & Human Services Fiscal Budget, 2015-2017

NATIONAL HEALTHCARE SAFETY NETWORK

  • Table 2-5: U.S. Hospital Acquired Infection Standardized Infection Ratio (SIR), 2010-2014
  • Figure 2-4: U.S. Hospital Acquired Infection Standardized Infection Ratio (SIR) 2012 through 2014

HEALTHCARE INFECTION SURVEILLANCE PROCESS

PHARMACEUTICAL MANUFACTURER AND MARKETER TRENDS

  • Trends in Partnerships and Alliances
  • Developers Trends

CHAPTER THREE: INFECTION PREVENTION

OVERVIEW

  • Table 3-1: Methods of Sterilization and Disinfection

MARKET OVERVIEW

  • Table 3-2: The Global Market for Hospital Infection Prevention Equipment and Consumables (Sterilization/Disinfection), 2010-2021
  • Healthcare Infection Prevention Market by Geographical Region
  • Table 3-3: The Global Market for Hospital Infection Prevention (Sterilization/Disinfection) Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total) .. 56
  • Methods of Transmission

HIGH-RISK FACILITIES OR DEPARTMENTS

  • Acute Care Hospitals
  • Long-term Care Facilities
  • Outpatient Settings
  • Technology Overview
  • Table 3-4: Market Value for Infection Prevention Equipment and Related Consumables by Product Type, 2016 (Medical Device/Instrument Sterilization, Wide-Area/Room Sterilization, Medical-grade Disinfection Solutions, Other Products, Total)
  • Sterilization vs. Disinfection

EQUIPMENT AND SOLUTIONS
Table 3-5: Market Value for Infection Prevention Equipment and Related Consumables by Technology, 2016 (Heat/Steam, Gas/Chemical, Ultrasound, Other, Total)

HEAT/STEAM STERILIZATION

  • Product Examples

CHEMICAL AND GAS STERILIZATION

  • Disinfecting Agents and Medical Device Components
  • Sterilants
  • Table 3-6: Summary of Advantages and Disadvantages of Chemical Agents Used as Chemical Sterilants or as High-Level Disinfectants
  • Table 3-7: Comparison of the Characteristics of Selected Chemicals Used as High-Level Disinfectants or Chemical Sterilants
  • Product Examples
  • Mid-Level Disinfectants
  • Table 3-8: Comparison of the Characteristics of Selected Hospital Disinfectants for General Disinfection of Environmental Surfaces

RADIATION STERILIZATION

  • Product Examples
  • Table 3-9: Developments, Healthcare Infection Prevention

COMPETITIVE ANALYSIS
Table 3-10: The Global Market for Hospital Infection Prevention (Sterilization/Disinfection), Leading Suppliers’ Shares, Estimates for 2016

CHAPTER FOUR: INFECTION TESTING
OVERVIEW
TOTAL MARKET SIZE AND FORECAST

  • Table 4-1: The Global Market for Hospital Infection Testing/Diagnostics, 2010-2021
  • Healthcare Infection Testing Market by Geographical Region
  • Table 4-2: The Global Market for Hospital Infection Testing/Diagnostics, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)

TESTING FOR NOSOCOMIAL INFECTIONS

  • Drug-Resistance/Susceptibility Testing
  • Genotypic Methods

DNA Sequencing

  • Solid-phase Hybridization Techniques
  • Hospital Acquired Infection (HAI) Control Markets
  • Microarrays
  • Real-time Polymerase Chain Reaction Techniques
  • Phenotypic Methods
  • Phage-based Assays
  • Colorimetric Methods
  • The Nitrate Reductase Assay
  • Chromogenic Testing
  • Table 4-3: Market Value for Nosocomial Infection Diagnostics by Class, 2016 (Immunoassays, Microbial Identification / Antimicrobial Sensitivity (ID/AST), Molecular DNA, Total)

SPECIFIC SERIOUS HEALTHCARE INFECTION TESTING

  • Table 4-4: Tested Samples, Pathogens Isolated by Infection Type (Surgical Site Infection [SSI], Central Line-associated Bloodstream Infections [CLABSI], Catheter-associated Urinary Tract Infections [CAUTI])
  • Acinetobacter Baumannii
  • Carbapenem-resistant Enterobacteriaceae
  • Clostridium Difficile
  • Product Examples
  • Hospital-Acquired Pneumonia
  • Pseudomonas Aeruginosa
  • Staphylococcus Aureus
  • Ventilator-Associated Pneumonia
  • Table 4-5: Significant Approvals for Detecting Serious Healthcare Infections
  • Figure 4-1: HAI Test Approvals in the U.S. by Year and Type, 2000-2016 (Staph/MRSA, C. diff, Others)
  • Figure 4-2: Distribution of Diagnostic Test Approvals with HAI Indications by Pathogen, All Approvals, 2000-2016 (MRSA, C. diff, CRE, VRE, GBS, Others)
  • Table 4-6: Market Value for Nosocomial Infection Diagnostics by Pathogen Target, 2016 (C. difficile Infections; MRSA Infections; Enterococcus, vancomycin-resistant; Enterobacteriaceae, carbapenem-resistant; M Tuberculosis; Others; Total)

DEVELOPMENTS

  • Table 4-7: Ongoing Developments, Healthcare Infection Testing
  • Table 4-8: Pathogen/Infection Detection Trials by Type

COMPETITIVE ANALYSIS

  • Table 4-9: The Global Market for Hospital Infection Testing/Diagnostics Leading Suppliers’ Shares Estimates for 2016

CHAPTER FIVE: INFECTION TREATMENT
OVERVIEW
TOTAL MARKET SIZE AND FORECAST

  • Table 5-1: The Global Market for Hospital Infection Treatment, 2010-2021
  • Healthcare Infection Treatment Market by Geographical Region
  • Table 5-2: The Global Market for Hospital Infection Treatment Estimated Products, Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)

PRINCIPLES OF ANTI-BACTERIAL THERAPY

  • Infecting Organism
  • Antibiotic Sensitivity Testing
  • Site of Infection
  • Host Defenses and Organ Function
  • Antibiotic Pharmacokinetics
  • Monitoring Therapy

CLASSIFICATIONS OF ANTIBACTERIAL PRODUCTS

  • Aminoglycosides
  • Carbapenems
  • Cephalosporins
  • Glycopeptides
  • Macrolides
  • Penicillins
  • Quinolones
  • Sulfonamides
  • Tetracyclines

MARKET SIZE AND SALES DISTRIBUTION BY ANTIBIOTIC CLASS

  • Table 5-3: Market Value for Nosocomial Infection Treatments by Class, 2016 (Quinolones, Glycopeptides, ß-lactamase inhibitors, Tetracyclines, Oxazolidinones, Macrolides, Carbapenems, Cephalosporins, Penicillins, Combinations, Others, Total)
  • Table 5-4: Nosocomial Infection Drug Candidates by Class, 2016 (Quinolones, Glycopeptides, Aminoglycosides, Tetracyclines, Oxazolidinones, Macrolides, Pleuromutilins, Cephalosporins, Fabl inhibitors, Combinations, Others, Total)

INFECTIONS AND DRUG RESISTANCE

  • Easing Approvals of Antibiotics
  • Table 5-5: CDER NME NDAs/BLAs Filings and Approvals as of 12/9/15

QUALIFIED INFECTIOUS DISEASE PROGRAM DESIGNATIONS

  • Causes of Drug Resistance
  • Drug Resistance in Select Populations
  • Treatment Guidelines
  • Table 5-6: Antibiotics with Difficult Penetration
  • Table 5-7: Market Value for Nosocomial Infection Treatments by Pathogen Target, 2016 (ABSSSI, cUTI, MRSA Infections, HAP/VAP, C. Difficile Infections, Others, Total)

NEW DEVELOPMENTS

  • Table 5-8: New Developments, Healthcare Infection Treatments, as of December 2016
  • Table 5-9: Infection Treatments in Development by Phase, as of December 2016
  • Table 5-10: Infection Treatment Drugs in Development by Route of Administration, as of December 2016
  • New Developments in Biotherapies for Infection Treatment

COMPETITIVE ANALYSIS

  • Table 5-11: The Global Market for Hospital Infection Treatment, Leading Suppliers' Shares, Estimated Share for HAIs for 2016
  • Table 5-12: Select Treatment Options for Serious Bacterial Infections (Type, Brand, and Manufacturer) .. 166
  • Leading Products
  • Table 5-13: Annual Sales of Select Antibacterial Products, 2016

CHAPTER SIX: MARKET OPPORTUNITIES FOR HOSPITAL INFECTION CONTROL
MARKET CONSIDERATIONS
MARKET OVERVIEW

  • Table 6-1: The Global Market for Hospital Infection Control, 2010-2021
  • Figure 6-1: The Global Market for Hospital Infection Control, 2010-2021
  • Figure 6-2: The Global Market for Hospital Infection Control, Estimated Market Share by Segment, 2016 (Treatment, Prevention, Testing)
  • Healthcare-Acquired Infection Distribution by Setting
  • Figure 6-3: The Global Market for Hospital Infection Control Estimated Market Share by Facility Setting, 2016 (Hospitals, Outpatient Servicing Centers, Dialysis Centers, Nursing Homes, Community Clinics, Others)
  • Figure 6-4: The Global Market for Hospital Infection Control Estimated Market Share by Hospital Department, 2016 (ICU, Med/Surg, Pediatrics, Others)
  • Healthcare Infection Control Market by Geographical Region
  • Table 6-2: The Global Market for Hospital Infection Control, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • Figure 6-5: The Global Market for Hospital Infection Control, Estimated Product Sales by Geographic Region, 2010-2021 (United States, Europe, Rest of World)
  • Figure 6-6: The Global Market for Hospital Infection Control, Estimated Market Share by Geographic Region, 2016 (%) (United States, Europe, Rest of World)
  • Developed and Emerging Market Analysis
  • Table 6-3: Developed vs. Emerging Markets
  • Figure 6-7: The Global Market for Hospital Infection Control, Estimated Market Share by Region, 2016 (%) (Developed Europe, Emerging Europe, United States, Rest of World [Japan, India, Canada, Brazil, China, Mexico, Africa, Other Developed, Other Emerging])

CHAPTER SEVEN: COMPANY PROFILES
INTRODUCTION

  • Figure 7-1: Global Markets for HAI by Participant and Segment (Infection Prevention, Infection Diagnostics, Infection Treatment)

3M

  • Table 7-1: 3M Company Corporate Summary
  • Company Overview
  • Company Performance

ABBOTT LABORATORIES

  • Table 7-2: Abbott Laboratories Corporate Summary
  • Company Overview
  • Company Performance

ABBVIE

  • Table 7-3: AbbVie Corporate Summary
  • Company Overview
  • Company Performance

ADVANCED STERILIZATION PRODUCTS

  • Table 7-4: Advanced Sterilization Products Corporate Summary
  • Company Overview
  • Company Performance

ALERE

  • Table 7-5: Alere Corporate Summary
  • Company Overview
  • Company Performance

ASTRAZENECA

  • Table 7-6: AstraZeneca Corporate Summary
  • Company Overview
  • Company Performance

BAYER

  • Table 7-7: Bayer Corporate Summary
  • Company Overview
  • Company Performance

BECTON, DICKINSON AND COMPANY

  • Table 7-8: Becton, Dickinson Corporate Summary
  • Company Overview
  • Company Performance

BELIMED

  • Table 7-9: Belimed Corporate Summary
  • Company Overview
  • Company Performance

BIOMÉRIEUX S.A.

  • Table 7-10: bioMérieux Corporate Summary
  • Company Overview
  • Company Performance

CANTEL MEDICAL CORP.

  • Table 7-11: Cantel Medical Corporate Summary
  • Company Overview
  • Company Performance

DANAHER CORPORATION

  • Table 7-12: Danaher Corporate Summary
  • Company Overview
  • Company Performance

ECOLAB, INC.

  • Table 7-13: Ecolab Corporate Summary
  • Company Overview
  • Company Performance

GETINGE GROUP

  • Table 7-14: Getinge AB Corporate Summary
  • Company Overview
  • Company Performance

GLAXOSMITHKLINE PLC

  • Table 7-15: GlaxoSmithKline Corporate Summary
  • Company Overview
  • Company Performance

MERCK & CO.

  • Table 7-16: Merck Corporate Summary
  • Company Overview
  • Company Performance

PFIZER, INC.

  • Table 7-17: Pfizer Corporate Summary
  • Company Overview
  • Company Performance

ROCHE

  • Table 7-18: F. Hoffman-La Roche, Ltd. Corporate Summary
  • Company Overview
  • Company Performance

SAKURA SEIKI CO., LTD.

  • Table 7-19: Sakura Seiki Corporate Summary
  • Company Overview

STERIS PLC

  • Table 7-20: Steris Corporate Summary
  • Company Overview
  • Company Performance

TSO3, INC.

  • Table 7-21: TSO3 Corporate Summary
  • Company Overview
  • Company Performance

APPENDIX: LIST OF PARTICIPANTS
Table A-1: List of Participants

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
  • 3M
  • Abbott Laboratories
  • Abbvie
  • Advanced Sterilization Products
  • Alere
  • Astrazeneca
  • Bayer
  • Becton, Dickinson And Company
  • Belimed
  • Biomérieux S.A.
  • Cantel Medical Corp.
  • Danaher Corporation
  • Ecolab, Inc.
  • Getinge Group
  • Glaxosmithkline Plc
  • Merck & Co.
  • Pfizer, Inc.
  • Roche
  • Sakura Seiki Co., Ltd.
  • Steris Plc
  • TSO3, Inc.
Note: Product cover images may vary from those shown
5 of 6
The methodology is available for download below.
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll